VASCULAR BIOGENICS OPERATING AS VBL THERAPEUTICS
Vascular Biogenics Ltd., operating as VBL Therapeutics (VBLT) is a late-stage clinical bio-pharmaceutical company focused on oncology and inflammatory diseases. Founded in 2000 and based in Tel Aviv, Israel, VBL’s has built its clinical pipeline based on two proprietary platform technologies that leverage the body’s natural physiologic and genetic regulatory elements: The proprietary Vascular Targeting System™ (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels and a proprietary platform of small molecules, Lecinoxoids, for chronic immune-related . . .